These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24204943)

  • 1. Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.
    Opoku-Acheampong AB; Unis D; Henningson JN; Beck AP; Lindshield BL
    PLoS One; 2013; 8(10):e77738. PubMed ID: 24204943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates.
    Opoku-Acheampong AB; Henningson JN; Lindshield BL
    Heliyon; 2017 Jul; 3(7):e00360. PubMed ID: 28765837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5α-reductase type 1 modulates insulin sensitivity in men.
    Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Vicentini C; Bologna M
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):243-54. PubMed ID: 15650886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
    Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV
    J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5α-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.
    Opoku-Acheampong AB; Henningson JN; Beck AP; Lindshield BL
    PLoS One; 2017; 12(5):e0175874. PubMed ID: 28493878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
    Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
    Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expectant management of localized prostate cancer--who, what, when, where and how?
    Ehdaie B
    J Urol; 2012 Sep; 188(3):696-7. PubMed ID: 22818346
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical applications of five-alpha reductase inhibitors.
    Loughlin KR
    Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
    Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
    Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 5 alpha-reductase inhibitors in the management of prostate cancer.
    Hudak SJ; Hernandez J; Thompson IM
    Clin Interv Aging; 2006; 1(4):425-31. PubMed ID: 18046919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer].
    Schulman C
    Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S35-42. PubMed ID: 15651489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
    J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.